<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457221</url>
  </required_header>
  <id_info>
    <org_study_id>F506-CL-0912</org_study_id>
    <nct_id>NCT02457221</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis</brief_title>
  <official_title>A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for
      induction remission in patients with lupus nephritis, and compare the efficacy and safety
      with Cyclophosphamide injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open, 1:1 parallel controlled, multi-center, non-inferiority clinical
      study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete remission + partial remission)</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>complete remission: urine protein &lt; 0.5g/24hr, and serum albumin≥3.5g/dl, and stable renal function (Scr increase ≤ 15% baseline value) partial remission: urine protein 0.5-3.5g/24hr (≥ 0.5 g/24hr and &lt; 3.5 g/24hr), and urine protein decreased by &gt;50% comparing with the baseline, and serum albumin ≥ 3.0g/dl, and stable renal function (Scr increase ≤ 15% baseline value)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour urine protein</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 24-hour urine protein from baseline</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum albumin from baseline</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum creatinine from baseline</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR comparing with baseline</measure>
    <time_frame>at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24</time_frame>
    <description>eGFR: Estimated Glomerular Filtration Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients converted to other immunosuppressive therapy</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with serum creatinine rising to two times of the baseline</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with dsDNA and ANA converting from positive to negative</measure>
    <time_frame>during 24 weeks</time_frame>
    <description>ANA: Antinuclear Antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLE-DAI</measure>
    <time_frame>at Week 4, 12 and 24</time_frame>
    <description>SLE-DAI: Systemic Lupus Erythematosus - Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune parameters assessed by ESR, C3, C4 and dsDNA</measure>
    <time_frame>at Week 4, 12 and 24</time_frame>
    <description>ESR: Erythrocyte Sedimentation Rate, C3, C4: Complement C3, C4, dsDNA: Anti-Double-Stranded DNA Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SLE-DAI from baseline</measure>
    <time_frame>at Week 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of immune parameters from baseline</measure>
    <time_frame>at Week 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal biopsy AI (Active Index)</measure>
    <time_frame>at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CI (Chronic Index)</measure>
    <time_frame>at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Renal biopsy AI (Active Index) from baseline</measure>
    <time_frame>at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CI (Chronic Index) from baseline</measure>
    <time_frame>at Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus capsules + steroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide injections + steroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus capsules</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide injections</intervention_name>
    <description>intravenous injection</description>
    <arm_group_label>Cyclophosphamide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>oral</description>
    <arm_group_label>Cyclophosphamide group</arm_group_label>
    <arm_group_label>Tacrolimus group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18.5≤Body Mass Index (BMI) &lt;27;

          -  Diagnosed as systemic lupus erythematosus (based on American Rheumatism Association
             Diagnostic Criteria 1997)

          -  Diagnosed as III, IV, V, III + V, IV + V lupus nephritis (according to the LN
             classification in International Society of Nephrology and Renal Pathology Society
             (ISN/RPS) 2003) within 24 weeks before enrollment with renal biopsy;

          -  24-hour urine protein ≥ 1.5g, Scr&lt;260umol/L (or 3mg/dL)

        Exclusion Criteria:

          -  Class II or VI lupus nephritis or renal biopsy chronic index (CI) &gt; 3 or with TMA;

          -  Received immunosuppressants (mycophenolate mofetil (MMF), cyclosporine, methotrexate,
             mechlorethamine, chlorambucil, tripterygium preparations, leflunomide etc.) treatment
             with a duration of more than one week within 30 days prior to enrollment;

          -  Received tacrolimus (except for topical use) or cyclophosphamide treatment within 30
             days prior to enrollment;

          -  Received a course of methylprednisolone (MP) pulse therapy or gamma globulin treatment
             or plasma exchange within 30 days prior to enrollment;

          -  Patients with history of allergies to tacrolimus, cyclophosphamide or
             methylprednisolone;

          -  Pregnancy, lactation or patient unwilling to take contraceptive measures;

          -  Patients with estimated maintenance dialysis for more than eight weeks; or dialysis
             for more than two weeks prior to entering observation;

          -  Patients received kidney transplantation or plan to have kidney transplantation
             recently;

          -  Serum creatinine (Scr) ≥260umol/L (or 3mg/dL) or creatinine clearance rate (Ccr) &lt;
             30ml/(min.1.73m2); according to Cockcroft-Gault formula: Ccr (ml/sec) = [(140- age)×
             Weight (kg)] × K / [72×Scr (umol/L) ×0.6786], Female K = 0.85, Male K = 1.0;

          -  Patients suffering from liver dysfunction (aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) more than 3 times the upper limit of normal lab value) or
             bilirubin more than 3 times the upper limit of normal lab value;

          -  Patients diagnosed with diabetes;

          -  History of gastrointestinal bleeding or pancreatitis within 3 months;

          -  Uncontrollable hyperkalemia after dietary therapy or reduction of potassium treatment
             (exceed the upper limit of normal lab value);

          -  Patients suffering from lupus pneumonia or lung injury;

          -  Patients with anemia (hemoglobin &lt;7g/dl) or bone marrow suppression (WBC &lt;3.0×109/L,
             and/or neutrophils &lt;1.5×109/L, and/or platelets &lt;50×109/L) not secondary to systemic
             lupus erythematosus;

          -  With congenital heart disease, arrhythmia, heart failure or other severe
             cardiovascular diseases;

          -  With refractory hypertension (defined as blood pressure still exceeds 180/110 mmHg
             despite taking three different types of antihypertensive drugs [one of them is
             diuretic] simultaneously);

          -  Patients with recurrent tumors within 5 years;

          -  Severe infection that requires intravenous antibiotics within 2 weeks prior to
             enrollment;

          -  Patients with infection of hepatitis B virus or hepatitis C virus; patients with
             active tuberculosis; patients with severe immunodeficiency diseases (including active
             cytomegalovirus infection (positive CMV IgM antibody), or human immunodeficiency virus
             (HIV) infection, etc.);

          -  Patients with lupus encephalopathy or other life-threatening complication of systemic
             lupus erythematosus;

          -  Patients participated in other clinical trials within three months before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma China, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site CN00043</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00030</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00034</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00041</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00056</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00017</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00045</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00037</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00038</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00020</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00047</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00028</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00023</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00024</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00027</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00050</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00012</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00013</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00025</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00049</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00026</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00042</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00005</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00018</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00019</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00032</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00001</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00014</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00015</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00052</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00002</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00003</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00021</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00044</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00010</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>May 19, 2018</last_update_submitted>
  <last_update_submitted_qc>May 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Prograf</keyword>
  <keyword>lupus nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

